Table 1 Study participant demographics and summary table.

From: The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD

Demographics

Number of patients recruited to study

65

Patient sex

48% (n = 31) male: 52% (n = 34) female

Patient age (mean, SD)

79.7 (SD = 8.6)

Smoking Status

Current Smoker: 11% (n = 7)

Ex-Smoker: 46% (n = 30)

Non-smoker: 43% (n = 28)

Body Mass Index (BMI) (mean, SD)

26.8 (SD = 3.94)

Co-morbidities

Hypertension: 47.7% (n = 31)

Asthma or COPD: 13.8% (n = 9)

Hyperlipidaemia: 13.8% (n = 9)

Diabetes (Type I or II): 12.3% (n = 8)

Nil co-morbidities declared: 16.9% (n = 11)

Mean Ranibizumab intravitreal injections over six, monthly follow-ups (mean, SD)

1.94 (SD = 0.98)

Serum Inflammatory Protein; Units

Serum Concentration (Cohort): 1st Quartile; Median; 3rd Quartile; Variance

C-Reactive Protein (CRP)

1.23 mg/L; 2.81 mg/L; 7.82 mg/L; 571.21 mg/L

Tumour Necrosis Factor-α (TNF-α)

0.098 pg/ml; 0.136 pg/ml; 0.179 pg/ml; 0.078 pg/ml

Interleukin-1β (IL-1β)

0.004 pg/ml; 0.010 pg/ml; 0.023 pg/ml; 0.012 pg/ml

Interleukin-2 (IL-2)

0.009 pg/ml; 0.017 pg/ml; 0.033 pg/ml; 0.010 pg/ml

Interleukin-6 (IL-6)

0.180 pg/ml; 0.300 pg/ml; 0.492 pg/ml; 2.723 pg/ml

Interleukin-8 (IL-8)

0.964 pg/ml; 1.462 pg/ml; 2.067 pg/ml; 61.87 pg/ml

Complement Pathway Activity*

Percentage activity relative to positive control (Cohort) 1st Quartile; Median; 3rd Quartile

Classical Complement Pathway (CP)

95.57%; 102.2%; 117.1%;

Alternative Complement Pathway (AP)

89.29%; 97.27%; 115.7%;

Gene sequencing analysis undertaken on patient cohort

Gene/DNA region

Reference SNP

Chromosome and Position (bp)

Major/Minor Allele

MAF

OR

Reference

CFH region

rs1061170

Chr 1; 196,659,237

T/C

0.61

2.41

11

CFI region

rs10033900

Chr 4; 110,659,067

C/T

0.52

1.18

11

SERPING1/C1-INH

rs2511989

Chr 11; 57,134,901

G/A

0.45

0.63

15

CFB

rs641153

Chr 6; 31,914,180

C/T

0.05

0.54

11

C2

rs9332739

Chr 6; 31,903,804

G/C

0.02

0.46

11

C3

rs2230199

Chr 19; 6,718,387

G/C

0.24

1.53

11

  1. SD standard deviation, SNP single nucleotide polymorphism, MAF minor allele frequency, OR odds ratio of AMD.
  2. *Measurement of classical or alternative complement pathway activity is expressed as a percentage relative to the fluorescence intensity of a positive control.
Back to article page